These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 24914348)

  • 1. Prognostic significance of SUVmax and serum carbohydrate antigen 19-9 in pancreatic cancer.
    Zhao JG; Hu Y; Liao Q; Niu ZY; Zhao YP
    World J Gastroenterol; 2014 May; 20(19):5875-80. PubMed ID: 24914348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preoperative maximum standardized uptake value and carbohydrate antigen 19-9 were independent predictors of pathological stages and overall survival in Chinese patients with pancreatic duct adenocarcinoma.
    Gu X; Zhou R; Li C; Liu R; Zhao Z; Gao Y; Xu Y
    BMC Cancer; 2019 May; 19(1):456. PubMed ID: 31092213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of preoperative fluorodeoxyglucose positron emission tomography/computed tomography in patients with potentially resectable pancreatic cancer.
    Omiya Y; Ichikawa S; Satoh Y; Motosugi U; Nakajima N; Onishi H
    Abdom Radiol (NY); 2018 Dec; 43(12):3381-3389. PubMed ID: 30043215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Combination of Neutrophil-to-lymphocyte Ratio and Serum Carbohydrate Antigen 19-9 Level as a Prognostic Indicator in Patients with Recurrent Pancreatic Cancer.
    Sakamoto T; Saito H; Uchinaka EI; Morimoto M; Amisaki M; Tokuyasu N; Honjo S; Ashida K; Fujiwara Y
    Anticancer Res; 2018 Sep; 38(9):5497-5503. PubMed ID: 30194208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Which is the best monitoring study (tumor marker, computed tomography or 18F-fluoro-2-deoxy-D-glucose positron emission tomography) to evaluate efficacy of chemotherapy on unresectable pancreatic cancer ?].
    Kobayashi N; Fujita K; Fujisawa T; Takahashi H; Yoneda M; Abe Y; Inamori M; Kirikoshi H; Kubota K; Saito S; Nakajima A
    Gan To Kagaku Ryoho; 2008 Jan; 35(1):65-70. PubMed ID: 18195530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnosis of pancreatic cancer using ¹⁸F-FDG PET/CT and CA19-9 with SUVmax association to clinical characteristics.
    Sun Y; Duan Q; Wang S; Zeng Y; Wu R
    J BUON; 2015; 20(2):452-9. PubMed ID: 26011335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined pretreatment serum CA19-9 and neutrophil-to-lymphocyte ratio as a potential prognostic factor in metastatic pancreatic cancer patients.
    Song JY; Chen MQ; Guo JH; Lian SF; Xu BH
    Medicine (Baltimore); 2018 Jan; 97(4):e9707. PubMed ID: 29369199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the prognostic impact of pre- and post-operative CA19-9, SPan-1, and DUPAN-II levels in patients with pancreatic carcinoma.
    Kondo N; Murakami Y; Uemura K; Nakagawa N; Takahashi S; Ohge H; Sueda T
    Pancreatology; 2017; 17(1):95-102. PubMed ID: 27746094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preoperative carbohydrate antigen 19-9 and standard uptake value of positron emission tomography-computed tomography as prognostic markers in patients with pancreatic ductal adenocarcinoma.
    Moon D; Kim H; Han Y; Byun Y; Choi Y; Kang J; Kwon W; Jang JY
    J Hepatobiliary Pancreat Sci; 2022 Oct; 29(10):1133-1141. PubMed ID: 33063453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CT response of primary tumor and CA19-9 predict resectability of metastasized pancreatic cancer after FOLFIRINOX.
    Tanaka M; Heckler M; Mihaljevic AL; Sun H; Klaiber U; Heger U; Büchler MW; Hackert T
    Eur J Surg Oncol; 2019 Aug; 45(8):1453-1459. PubMed ID: 30981446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between S100A4 protein expression and pre-operative serum CA19.9 levels in pancreatic carcinoma and its prognostic significance.
    Jia F; Liu M; Li X; Zhang F; Yue S; Liu J
    World J Surg Oncol; 2019 Sep; 17(1):163. PubMed ID: 31526392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term survival after resection of pancreatic cancer: a single-center retrospective analysis.
    Yamamoto T; Yagi S; Kinoshita H; Sakamoto Y; Okada K; Uryuhara K; Morimoto T; Kaihara S; Hosotani R
    World J Gastroenterol; 2015 Jan; 21(1):262-8. PubMed ID: 25574100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study.
    Dong Q; Yang XH; Zhang Y; Jing W; Zheng LQ; Liu YP; Qu XJ
    World J Surg Oncol; 2014 Jun; 12():171. PubMed ID: 24890327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CA19-9 level determines therapeutic modality in pancreatic cancer patients with para-aortic lymph node metastasis.
    Asaoka T; Miyamoto A; Maeda S; Hama N; Tsujie M; Ikeda M; Sekimoto M; Nakamori S
    Hepatobiliary Pancreat Dis Int; 2018 Feb; 17(1):75-80. PubMed ID: 29428109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A varying-coefficient cox model for the effect of CA19-9 kinetics on overall survival in patients with advanced pancreatic cancer.
    Chen Y; Shao Z; Chen W; Xie H; Wu Z; Qin G; Zhao N
    Oncotarget; 2017 May; 8(18):29925-29934. PubMed ID: 28404893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic impact of preoperative NLR and CA19-9 in pancreatic cancer.
    Asaoka T; Miyamoto A; Maeda S; Tsujie M; Hama N; Yamamoto K; Miyake M; Haraguchi N; Nishikawa K; Hirao M; Ikeda M; Sekimoto M; Nakamori S
    Pancreatology; 2016; 16(3):434-40. PubMed ID: 26852169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preoperative prediction of disease-free survival in pancreatic ductal adenocarcinoma patients after R0 resection using contrast-enhanced CT and CA19-9.
    Li D; Peng Q; Wang L; Cai W; Liang M; Liu S; Ma X; Zhao X
    Eur Radiol; 2024 Jan; 34(1):509-524. PubMed ID: 37507611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic and predictive value of serum CA19.9 in pancreatic cancer.
    Humphris JL; Chang DK; Johns AL; Scarlett CJ; Pajic M; Jones MD; Colvin EK; Nagrial A; Chin VT; Chantrill LA; Samra JS; Gill AJ; Kench JG; Merrett ND; Das A; Musgrove EA; Sutherland RL; Biankin AV;
    Ann Oncol; 2012 Jul; 23(7):1713-22. PubMed ID: 22241899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of the neutrophil-to-lymphocyte ratio and carbohydrate antigen 19-9 in estimating survival in patients with metastatic pancreatic cancer.
    Cetin S; Dede I
    J Cancer Res Ther; 2020; 16(4):909-916. PubMed ID: 32930139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Applicative Value of Serum CA19-9, CEA, CA125 and CA242 in Diagnosis and Prognosis for Patients with Pancreatic Cancer Treated by Concurrent Chemoradiotherapy.
    Gu YL; Lan C; Pei H; Yang SN; Liu YF; Xiao LL
    Asian Pac J Cancer Prev; 2015; 16(15):6569-73. PubMed ID: 26434876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.